Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

High Risk MDS or AML Patients Clinical Trial

Official title: Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

Status Completed

Clinical Trial Summary

The purpose of this trial is to examine the hematologic response rate of Exjade® in patients with AML and high risk MDS and chronic iron overload from blood transfusions. Deferasirox has been developed as an iron-chelating agent, and unlike deferoxamine, a previously developed iron chelator, deferasirox has the advantage of oral administration.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• High Risk MDS or AML Patients
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Preleukemia

• NCT number: NCT02233504
• Study type: Interventional
• Source: Abramson Cancer Center of the University of Pennsylvania
• Status: Completed
• Phase: Early Phase 1
• Start date: August 2014
• Completion date: October 2, 2017